

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Various				
Inflammation; cancer	ADAM17	<p><i>In vitro</i> studies identified an anti-ADAM17 antibody that could help treat inflammatory diseases. Metallopeptidase family members have conserved catalytic domains that have made it challenging to develop specific inhibitors. In a metallopeptidase activity assay, the new antibody inhibited ADAM17 activity at nanomolar concentration but did not inhibit ADAM10, a closely related metallopeptidase. Next steps could include testing the therapeutic potential of the antibody in animal models of inflammatory diseases. Incyte Corp.'s INCB7839, a small molecule ADAM10 and ADAM17 inhibitor, is in Phase II testing in combination with Herceptin trastuzumab from Roche's Genentech Inc. unit to treat HER2 (EGFR2; ERBB2; neu)-positive breast cancer.</p> <p>SciBX 4(13); doi:10.1038/scibx.2011.380 Published online March 31, 2011</p>	Patent and licensing status undisclosed	<p>Tape, C.J. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online March 17, 2011; doi:10.1073/pnas.1017067108 Contact: Gillian Murphy, University of Cambridge, Cambridge, U.K. e-mail: gm290@cam.ac.uk</p>